Want to see TXG full AI Analyst Report?
Revenue by Segment
Breaks down revenue by business segment, illustrating the company's diverse income streams and identifying which areas contribute most to overall growth and stability.10x Genomics' Subscription Services segment shows robust growth, reflecting a strategic shift towards recurring revenue models. However, the Instruments segment faces significant challenges, with a 39% revenue decline due to decreased demand and pricing pressures. The Consumables segment remains stable, supported by growth in spatial consumables. Despite a challenging academic funding environment, the company is leveraging strategic acquisitions like Scale Biosciences to enhance capabilities. The recent favorable patent settlement and strong performance in China provide financial cushioning, but ongoing CapEx constraints and U.S. revenue declines pose risks.
Date | Subscription Services | Consumables | Instruments | License and Royalty |
|---|---|---|---|---|
Jun 30, 2026 | $10.68M | $130.75M | $7.66M | $1.94M |
Mar 31, 2026 | $8.83M | $129.80M | $11.26M | $947.00K |
Dec 31, 2025 | $8.47M | $141.75M | $15.47M | $341.00K |
Sep 30, 2025 | $9.11M | $127.89M | $12.00M | $983.00K |
Jun 30, 2025 | $8.47M | $122.19M | $14.50M | $27.75M |
Mar 31, 2025 | $7.65M | $115.36M | $14.81M | $17.06M |
Dec 31, 2024 | $7.02M | $133.53M | $24.35M | $111.00K |
Sep 30, 2024 | $6.39M | $126.20M | $19.06M | $95.00K |
Jun 30, 2024 | $5.89M | $123.36M | $23.85M | $114.00K |
Mar 31, 2024 | $5.22M | $110.33M | $25.45M | $1.00K |